25128-32-9

Basic information

• Product Name: 2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID
• Synonyms: CHEMBRDG-BB 4012386;5-CARBOXYISATIN;2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID;2,3-Dioxo-2,3-dihydro-1H-indole-5-carboxylic acid
• CAS NO: 25128-32-9
• Molecular Formula: C₉H₅NO₄
• Molecular Weight: 191.14
• Mol File: 25128-32-9.mol

Chemical Properties

• Melting Point: 295 °C(Solv: acetic acid (64-19-7))
• Appearance: /
• Density: 1.591g/cm³
• Refractive Index: 1.66
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.56±0.20(Predicted)
• CAS DataBase Reference: 2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID(25128-32-9)
• EPA Substance Registry System: 2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID(25128-32-9)

Safety Data

• Hazardous Substances Data: 25128-32-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2,3-Dioxoindoline-5-carboxylic acid is used as a key intermediate in the synthesis of pharmaceutical drugs and natural products. Its unique structure and reactivity make it a valuable component in the development of new medications.
Used in Chemical Production:
2,3-DIOXOINDOLINE-5-CARBOXYLIC ACID also serves as an intermediate in the production of other chemical compounds, contributing to the synthesis of a variety of organic molecules for different applications across various industries.

InChI:InChI=1/C9H5NO4/c11-7-5-3-4(9(13)14)1-2-6(5)10-8(7)12/h1-3H,(H,13,14)(H,10,11,12)

Upstream product

• 402-59-5 N-(4-trifluoromethylphenyl)-2-oxyiminoacetamide 
• 17122-78-0 4-(2-hydroxyimino-acetylamino)-benzoic acid 
• 302-17-0 chloral hydrate 
• 94-09-7 p-aminoethylbenzoate 
• 1238056-85-3 3-amino-5-carboxyoxindole hydrochloride 
• 953029-80-6 3,3-dibromo-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid methyl ester 
• 455-14-1 4-trifluoromethylphenylamine 
• 619-45-4 4-methoxycarbonyl aniline 
• 150-13-0 4-amino-benzoic acid 
• 17122-79-1 N-(4-ethoxycarbonylphenyl)-2-(hydroxyimino)acetamide 
• 66475-80-7 4-(2-hydroxyimino-acetylamino)-benzoic acid methyl ester 
• 345-32-4 5-(trifluoromethyl)isatin 

Downstream Products

• 924900-15-2 2,3-dioxo-N-phenylindoline-5-carboxamide 
• 924900-17-4 N-benzyl-2,3-dioxoindoline-5-carboxamide 
• 1238056-79-5 pentafluorophenyl isatin-5-carboxylate 
• 222036-96-6 2-oxo-3-[(4-sulfamoyl-phenyl)-hydrazono]-2,3-dihydro-1H-indole-5-carboxylic acid 
• 855764-18-0 2-phenylquinoline-4,6-dicarboxylic acid 
• 94574-75-1 3-hydroxy-2-phenyl-quinoline-4,6-dicarboxylic acid 
• 102359-00-2 2-oxoindoline-5-carboxylic acid 

Relevant articles and documents

Composition for Inhibiting or Treating for Acute Myeloid Leukemia or Metastatic Breast Cancer

The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer comprising an indirubin derivative as an active ingredient. Use of the composition of the invention effectively inhibits the activity of FLT3 kinase. A composition for preventing or treating acute myeloid leukemia or metastatic breast cancer is provided.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER

The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used,

Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives

A series of 3-methylene-2-oxoindoline-5-carboxamide derivatives were synthesized in appreciable yield by using 4-aminobenzoic acid as a starting material. The preliminary biological test results showed that most compounds displayed potent inhibitory activity against proliferation of human lung adenocarcinoma epithelial cell line (A549) in MTT assay. Compound 6l displayed the highest potency (IC50 = 3.0 μM). The western blot analysis demonstrated a correlation between anti-proliferative activity of active compounds and blockade of the phosphorylation of extracellular signal-regulated kinases (ERK1/2). The docking study also provides new insights into further optimization of 3-methylene-2-oxoindoline-5-carboxamide derivatives for the discovery of more potent RAF/MEK/ERK pathway regulators as anti-lung cancer agents.

The SARS coronavirus main protease having effects of inhibiting isatin - 5 - amide inhibitors

The invention provides an isatin-5-amide compound represented by a formula (1). The compound has an inhibition activity against SARS coronavirus main protease, and can be used as a SARS coronavirus main protease inhibiting agent, and can be applied in SAR

Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors

The Severe Acute Respiratory Syndrome (SARS) is a serious life-threatening and strikingly mortal respiratory illness caused by SARS-CoV. SARS-CoV which contains a chymotrypsin-like main protease analogous to that of the main picornavirus protease, 3CLpro. 3CLpro plays a pivotal role in the viral replication cycle and is a potential target for SARS inhibitor development. A series of isatin derivatives as possible SARS-CoV 3CL pro inhibitors was designed, synthesized, and evaluated by in vitro protease assay using fluorogenic substrate peptide, in which several showed potent inhibition against the 3CLpro. Structure-activity relationship was analyzed, and possible binding interaction modes were proposed by molecular docking studies. Among all compounds, 8k1 showed most potent inhibitory activity against 3CLpro (IC50 = 1.04 μM). These results indicated that these inhibitors could be potentially developed into anti-SARS drugs.

Identification and further development of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B

Tuberculosis continues to be a major cause of morbidity and mortality throughout the world. Protein tyrosine phosphatases from Mycobacterium tuberculosis are attractive targets for developing novel strategies in battling tuberculosis due to their role in

Synthesis and cytotoxicity of novel indirubin-5-carboxamides

Indirubins have been reported to act as potent inhibitors of protein kinases relevant to tumorigenesis and of tumor cell growth, but their development to antitumor drugs suffer from their poor water solubility. We synthesized a novel class of indirubin derivatives, indirubin-5-carboxamides, carrying amide substituents with basic centers. Quaternization or protonation of these alkylamino substituents provided indirubins with significantly improved solubility without loss of bioactivity.

Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds

Screening of the NCI diversity set of compounds has led to the identification of 5 (NSC-117199), which inhibits the protein tyrosine phosphatase (PTP) Shp2 with an IC50 of 47 μM. A focused library incorporating an isatin scaffold was designed a

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Leukocyte recruitment of sites of inflammation and tissue injury involves leukocyte rolling along the endothelial wall, followed by firm adherence of the leukocyte, and finally transmigration of the leukocyte across cell junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis. High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. Through iterative medicinal chemistry, we identified analogues with improved P-selectin activity, decreased inhibition of dihydrooratate dehydrogenase, and acceptable CYP profiles. Lead compound 36 was efficacious in the rat AIA model of rheumatoid arthritis.

Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors

A series of isatin derivatives were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-li